Recent submissions

  • Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. 

    Bird, S; Panopoulou, A; Shea, RL; Tsui, M; Saso, R; Sud, A; West, S; Smith, K; Barwood, J; Kaczmarek, E; Panlaqui, C; Kaiser, M; Stern, S; Pawlyn, C; Boyd, K (2021-04-19)
  • The use of germline genetic profiles to guide prostate cancer targeted screening and cancer care 

    Benafif, S (2020-09-30)
    The genetic heritability of prostate cancer is contributed to by rarely occurring but high penetrant genetic variants, and moderate to commonly occurring variants conferring lower risks. Genome wide association studies and ...
  • Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. 

    Pal Choudhury, P; Brook, MN; Hurson, AN; Lee, A; Mulder, CV; Coulson, P; Schoemaker, MJ; Jones, ME; Swerdlow, AJ; Chatterjee, N; Antoniou, AC; Garcia-Closas, M (2021-02-15)
    <h4>Background</h4>The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and the Tyrer-Cuzick breast cancer risk prediction models are commonly used in clinical practice and have ...
  • Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. 

    Saunders, EJ; Kote-Jarai, Z; Eeles, RA (2021-02-12)
    Prostate cancer (PrCa) is a heterogeneous disease, which presents in individual patients across a diverse phenotypic spectrum ranging from indolent to fatal forms. No robust biomarkers are currently available to enable ...
  • Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study. 

    Au, L; Fendler, A; Boos, LA; Byrnes, F; Shepherd, S; Nicholson, E; Kumar, S; Yousaf, N; Wilkinson, K; Swerdlow, A; Harvey, R; Kassiotis, G; Wilkinson, R; Larkin, J; Turajlic, S (AMER ASSOC CANCER RESEARCH, 2020-03-01)
  • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. 

    Coignard, J; Lush, M; Beesley, J; O'Mara, TA; Dennis, J; Tyrer, JP; Barnes, DR; McGuffog, L; Leslie, G; Bolla, MK; Adank, MA; Agata, S; Ahearn, T; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Arnold, N; Aronson, KJ; Arun, BK; Augustinsson, A; Azzollini, J; Barrowdale, D; Baynes, C; Becher, H; Bermisheva, M; Bernstein, L; Białkowska, K; Blomqvist, C; Bojesen, SE; Bonanni, B; Borg, A; Brauch, H; Brenner, H; Burwinkel, B; Buys, SS; Caldés, T; Caligo, MA; Campa, D; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Conroy, DM; Czene, K; Daly, MB; Devilee, P; Diez, O; Ding, YC; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Dwek, M; Eccles, DM; Eliassen, AH; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Flyger, H; Fostira, F; Friedman, E; Fritschi, L; Frost, D; Gago-Dominguez, M; Gapstur, SM; Garber, J; Garcia-Barberan, V; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Gayther, SA; Gehrig, A; Georgoulias, V; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; He, W; Hogervorst, FBL; Hollestelle, A; Hopper, JL; Horcasitas, DJ; Hulick, PJ; Hunter, DJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Jager, A; Jakubowska, A; James, PA; Jensen, UB; John, EM; Jones, ME; Kaaks, R; Kapoor, PM; Karlan, BY; Keeman, R; Khusnutdinova, E; Kiiski, JI; Ko, Y-D; Kosma, V-M; Kraft, P; Kurian, AW; Laitman, Y; Lambrechts, D; Le Marchand, L; Lester, J; Lesueur, F; Lindstrom, T; Lopez-Fernández, A; Loud, JT; Luccarini, C; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mebirouk, N; Meindl, A; Miller, A; Milne, RL; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nielsen, FC; O'Brien, KM; Olopade, OI; Olson, JE; Olsson, H; Osorio, A; Ottini, L; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peshkin, B; Peterlongo, P; Peto, J; Pharoah, PDP; Phillips, K-A; Polley, EC; Poppe, B; Presneau, N; Pujana, MA; Punie, K; Radice, P; Rantala, J; Rashid, MU; Rennert, G; Rennert, HS; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sandler, DP; Santella, R; Scheuner, MT; Schmidt, MK; Schmidt, G; Scott, C; Sharma, P; Soucy, P; Southey, MC; Spinelli, JJ; Steinsnyder, Z; Stone, J; Stoppa-Lyonnet, D; Swerdlow, A; Tamimi, RM; Tapper, WJ; Taylor, JA; Terry, MB; Teulé, A; Thull, DL; Tischkowitz, M; Toland, AE; Torres, D; Trainer, AH; Truong, T; Tung, N; Vachon, CM; Vega, A; Vijai, J; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wolk, A; Yadav, S; Yang, XR; Yannoukakos, D; Zheng, W; Ziogas, A; Zorn, KK; Park, SK; Thomassen, M; Offit, K; Schmutzler, RK; Couch, FJ; Simard, J; Chenevix-Trench, G; Easton, DF; Andrieu, N; Antoniou, AC (2021-02-17)
    Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in ...
  • Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. 

    Huynh-Le, M-P; Fan, CC; Karunamuni, R; Thompson, WK; Martinez, ME; Eeles, RA; Kote-Jarai, Z; Muir, K; Schleutker, J; Pashayan, N; Batra, J; Grönberg, H; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Nielsen, SF; Nordestgaard, BG; Wiklund, F; Tangen, CM; Giles, GG; Wolk, A; Albanes, D; Travis, RC; Blot, WJ; Zheng, W; Sanderson, M; Stanford, JL; Mucci, LA; West, CML; Kibel, AS; Cussenot, O; Berndt, SI; Koutros, S; Sørensen, KD; Cybulski, C; Grindedal, EM; Menegaux, F; Khaw, K-T; Park, JY; Ingles, SA; Maier, C; Hamilton, RJ; Thibodeau, SN; Rosenstein, BS; Lu, Y-J; Watya, S; Vega, A; Kogevinas, M; Penney, KL; Huff, C; Teixeira, MR; Multigner, L; Leach, RJ; Cannon-Albright, L; Brenner, H; John, EM; Kaneva, R; Logothetis, CJ; Neuhausen, SL; De Ruyck, K; Pandha, H; Razack, A; Newcomb, LF; Fowke, JH; Gamulin, M; Usmani, N; Claessens, F; Gago-Dominguez, M; Townsend, PA; Bush, WS; Roobol, MJ; Parent, M-É; Hu, JJ; Mills, IG; Andreassen, OA; Dale, AM; Seibert, TM; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium (2021-02-23)
    Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS<sub>1</sub>) is associated with age at prostate cancer diagnosis ...
  • Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. 

    Gonzalez, D; Mateo, J; Stenzinger, A; Rojo, F; Shiller, M; Wyatt, AW; Penault-Llorca, F; Gomella, LG; Eeles, R; Bjartell, A (2021-02-25)
    Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP-ribose) polymerase (PARP) ...
  • Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. 

    Lesseur, C; Ferreiro-Iglesias, A; McKay, JD; Bossé, Y; Johansson, M; Gaborieau, V; Landi, MT; Christiani, DC; Caporaso, NC; Bojesen, SE; Amos, CI; Shete, S; Liu, G; Rennert, G; Albanes, D; Aldrich, MC; Tardon, A; Chen, C; Triantafillos, L; Field, JK; Teare, MD; Kiemeney, LA; Diergaarde, B; Ferris, RL; Zienolddiny, S; Lam, S; Olshan, AF; Weissler, MC; Lacko, M; Risch, A; Bickeböller, H; Ness, AR; Thomas, S; Le Marchand, L; Schabath, MB; Wünsch-Filho, V; Tajara, EH; Andrew, AS; Clifford, GM; Lazarus, P; Grankvist, K; Johansson, M; Arnold, S; Melander, O; Brunnström, H; Boccia, S; Cadoni, G; Timens, W; Obeidat, M; Xiao, X; Houlston, RS; Hung, RJ; Brennan, P (2021-03-05)
    Squamous cell carcinomas (SqCC) of the aerodigestive tract have similar etiological risk factors. Although genetic risk variants for individual cancers have been identified, an agnostic, genome-wide search for shared genetic ...
  • Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. 

    Lin, W-Y; Fordham, SE; Sunter, N; Elstob, C; Rahman, T; Willmore, E; Shepherd, C; Strathdee, G; Mainou-Fowler, T; Piddock, R; Mearns, H; Barrow, T; Houlston, RS; Marr, H; Wallis, J; Summerfield, G; Marshall, S; Pettitt, A; Pepper, C; Fegan, C; Forconi, F; Dyer, MJS; Jayne, S; Sellors, A; Schuh, A; Robbe, P; Oscier, D; Bailey, J; Rais, S; Bentley, A; Cawkwell, L; Evans, P; Hillmen, P; Pratt, G; Allsup, DJ; Allan, JM (2021-01-28)
    Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid ...
  • Genetic predisposition to prostate cancer: an update. 

    Ni Raghallaigh, H; Eeles, R (2021-01-24)
    Improvements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate ...
  • CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. 

    Johnson, N; Maguire, S; Morra, A; Kapoor, PM; Tomczyk, K; Jones, ME; Schoemaker, MJ; Gilham, C; Bolla, MK; Wang, Q; Dennis, J; Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Baynes, C; Freeman, LEB; Beckmann, MW; Benitez, J; Bermisheva, M; Blomqvist, C; Boeckx, B; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Burwinkel, B; Campa, D; Canzian, F; Castelao, JE; Chanock, SJ; Chenevix-Trench, G; Clarke, CL; NBCS Collaborators; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dörk, T; Eliassen, AH; Engel, C; Evans, DG; Fasching, PA; Figueroa, J; Floris, G; Flyger, H; Gago-Dominguez, M; Gapstur, SM; García-Closas, M; Gaudet, MM; Giles, GG; Goldberg, MS; González-Neira, A; AOCS Group; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; Hooning, MJ; Hopper, JL; Howell, A; Hunter, DJ; ABCTB Investigators; kConFab Investigators; Jager, A; Jakubowska, A; John, EM; Kaaks, R; Keeman, R; Khusnutdinova, E; Kitahara, CM; Kosma, V-M; Koutros, S; Kraft, P; Kristensen, VN; Kurian, AW; Lambrechts, D; Le Marchand, L; Linet, M; Lubiński, J; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mavroudis, D; Mayes, R; Meindl, A; Milne, RL; Neuhausen, SL; Nevanlinna, H; Newman, WG; Nielsen, SF; Nordestgaard, BG; Obi, N; Olshan, AF; Olson, JE; Olsson, H; Orban, E; Park-Simon, T-W; Peterlongo, P; Plaseska-Karanfilska, D; Pylkäs, K; Rennert, G; Rennert, HS; Ruddy, KJ; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmutzler, RK; Scott, C; Shu, X-O; Simard, J; Smichkoska, S; Sohn, C; Southey, MC; Spinelli, JJ; Stone, J; Tamimi, RM; Taylor, JA; Tollenaar, RAEM; Tomlinson, I; Troester, MA; Truong, T; Vachon, CM; van Veen, EM; Wang, SS; Weinberg, CR; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Zheng, W; Ziogas, A; Dunning, AM; Pharoah, PDP; Easton, DF; Howie, AF; Peto, J; Dos-Santos-Silva, I; Swerdlow, AJ; Chang-Claude, J; Schmidt, MK; Orr, N; Fletcher, O (2021-01-26)
    BACKGROUND: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary ...
  • Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. 

    Glubb, DM; Thompson, DJ; Aben, KK; Alsulimani, A; Amant, F; Annibali, D; Attia, J; Barricarte, A; Beckmann, MW; Berchuck, A; Bermisheva, M; Bernardini, MQ; Bischof, K; Bjørge, L; Bodelon, C; Brand, AH; Brenton, JD; Brinton, LA; Bruinsma, F; Buchanan, DD; Burghaus, S; Bützow, R; Cai, H; Carney, ME; Chanock, SJ; Chen, C; Chen, X; Chen, Z; Cook, LS; Cunningham, JM; De Vivo, I; DeFazio, A; Doherty, JA; Dork, T; du Bois, A; Dunning, AM; Durst, M; Edwards, T; Edwards, RP; Ekici, AB; Ewing, A; Fasching, PA; Ferguson, S; Flanagan, JM; Fostira, F; Fountzilas, G; Friedenreich, CM; Gao, B; Gaudet, MM; Gawełko, J; Gentry-Maharaj, A; Giles, GG; Glasspool, R; Goodman, MT; Gronwald, J; Harris, HR; Harter, P; Hein, A; Heitz, F; Hildebrandt, MAT; Hillemanns, P; Høgdall, E; Høgdall, CK; Holliday, EG; Huntsman, DG; Huzarski, T; Jakubowska, A; Jensen, A; Jones, ME; Karlan, BY; Karnezis, A; Kelley, JL; Khusnutdinova, E; Killeen, JL; Kjaer, SK; Klapdor, R; Köbel, M; Konopka, B; Konstantopoulou, I; Kopperud, RK; Koti, M; Kraft, P; Kupryjanczyk, J; Lambrechts, D; Larson, MC; Le Marchand, L; Lele, S; Lester, J; Li, AJ; Liang, D; Liebrich, C; Lipworth, L; Lissowska, J; Lu, L; Lu, KH; Macciotta, A; Mattiello, A; May, T; McAlpine, JN; McGuire, V; McNeish, IA; Menon, U; Modugno, F; Moysich, KB; Nevanlinna, H; Odunsi, K; Olsson, H; Orsulic, S; Osorio, A; Palli, D; Park-Simon, T-W; Pearce, CL; Pejovic, T; Permuth, JB; Podgorska, A; Ramus, SJ; Rebbeck, TR; Riggan, MJ; Risch, HA; Rothstein, JH; Runnebaum, IB; Scott, RJ; Sellers, TA; Senz, J; Setiawan, VW; Siddiqui, N; Sieh, W; Spiewankiewicz, B; Sutphen, R; Swerdlow, AJ; Szafron, LM; Teo, SH; Thompson, PJ; Thomsen, LCV; Titus, L; Tone, A; Tumino, R; Turman, C; Vanderstichele, A; Velez Edwards, D; Vergote, I; Vierkant, RA; Wang, Z; Wang-Gohrke, S; Webb, PM; White, E; Whittemore, AS; Winham, SJ; Wu, X; Wu, AH; Yannoukakos, D; Spurdle, AB; O'Mara, TA (2020-11-03)
    BACKGROUND:Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and ...
  • Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. 

    Croft, J; Ellis, S; Sherborne, AL; Sharp, K; Price, A; Jenner, MW; Drayson, MT; Owen, RG; Chown, S; Lindsay, J; Karunanithi, K; Hunter, H; Gregory, WM; Davies, FE; Morgan, GJ; Cook, G; Atanesyan, L; Savola, S; Cairns, DA; Jackson, G; Houlston, RS; Kaiser, MF (2020-12)
    Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM), however their evolution in context of modern biological therapy is not well characterized. To investigate ...
  • 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population. 

    Takata, R; Takahashi, A; Fujita, M; Momozawa, Y; Saunders, EJ; Yamada, H; Maejima, K; Nakano, K; Nishida, Y; Hishida, A; Matsuo, K; Wakai, K; Yamaji, T; Sawada, N; Iwasaki, M; Tsugane, S; Sasaki, M; Shimizu, A; Tanno, K; Minegishi, N; Suzuki, K; Matsuda, K; Kubo, M; Inazawa, J; Egawa, S; Haiman, CA; Ogawa, O; Obara, W; Kamatani, Y; Akamatsu, S; Nakagawa, H (2019-09-27)
    Genome-wide association studies (GWAS) have identified ~170 genetic loci associated with prostate cancer (PCa) risk, but most of them were identified in European populations. We here performed a GWAS and replication study ...
  • Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. 

    Karlsson, Q; Brook, MN; Dadaev, T; Wakerell, S; Saunders, EJ; Muir, K; Neal, DE; Giles, GG; MacInnis, RJ; Thibodeau, SN; McDonnell, SK; Cannon-Albright, L; Teixeira, MR; Paulo, P; Cardoso, M; Huff, C; Li, D; Yao, Y; Scheet, P; Permuth, JB; Stanford, JL; Dai, JY; Ostrander, EA; Cussenot, O; Cancel-Tassin, G; Hoegel, J; Herkommer, K; Schleutker, J; Tammela, TLJ; Rathinakannan, V; Sipeky, C; Wiklund, F; Grönberg, H; Aly, M; Isaacs, WB; Dickinson, JL; FitzGerald, LM; Chua, MLK; Nguyen-Dumont, T; PRACTICAL Consortium; Schaid, DJ; Southey, MC; Eeles, RA; Kote-Jarai, Z (2021-01-09)
    Germline ATM mutations are suggested to contribute to predisposition to prostate cancer (PrCa). Previous studies have had inadequate power to estimate variant effect sizes. To precisely estimate the contribution of germline ...
  • The <i>CHEK2</i> Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. 

    Brandão, A; Paulo, P; Maia, S; Pinheiro, M; Peixoto, A; Cardoso, M; Silva, MP; Santos, C; Eeles, RA; Kote-Jarai, Z; Muir, K; Ukgpcs Collaborators; Schleutker, J; Wang, Y; Pashayan, N; Batra, J; Apcb BioResource; Grönberg, H; Neal, DE; Nordestgaard, BG; Tangen, CM; Southey, MC; Wolk, A; Albanes, D; Haiman, CA; Travis, RC; Stanford, JL; Mucci, LA; West, CML; Nielsen, SF; Kibel, AS; Cussenot, O; Berndt, SI; Koutros, S; Sørensen, KD; Cybulski, C; Grindedal, EM; Park, JY; Ingles, SA; Maier, C; Hamilton, RJ; Rosenstein, BS; Vega, A; The Impact Study Steering Committee And Collaborators; Kogevinas, M; Wiklund, F; Penney, KL; Brenner, H; John, EM; Kaneva, R; Logothetis, CJ; Neuhausen, SL; Ruyck, KD; Razack, A; Newcomb, LF; Canary Pass Investigators; Lessel, D; Usmani, N; Claessens, F; Gago-Dominguez, M; Townsend, PA; Roobol, MJ; The Profile Study Steering Committee; The Practical Consortium; Teixeira, MR (2020-11-04)
    The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence ...
  • Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. 

    Schaid, DJ; McDonnell, SK; FitzGerald, LM; DeRycke, L; Fogarty, Z; Giles, GG; MacInnis, RJ; Southey, MC; Nguyen-Dumont, T; Cancel-Tassin, G; Cussenot, O; Whittemore, AS; Sieh, W; Ioannidis, NM; Hsieh, C-L; Stanford, JL; Schleutker, J; Cropp, CD; Carpten, J; Hoegel, J; Eeles, R; Kote-Jarai, Z; Ackerman, MJ; Klein, CJ; Mandal, D; Cooney, KA; Bailey-Wilson, JE; Helfand, B; Catalona, WJ; Wiklund, F; Riska, S; Bahetti, S; Larson, MC; Cannon Albright, L; Teerlink, C; Xu, J; Isaacs, W; Ostrander, EA; Thibodeau, SN (2020-08-13)
    BACKGROUND:Family history of prostate cancer (PCa) is a well-known risk factor, and both common and rare genetic variants are associated with the disease. OBJECTIVE:To detect new genetic variants associated with PCa, ...
  • FRMD6 has tumor suppressor functions in prostate cancer. 

    Haldrup, J; Strand, SH; Cieza-Borrella, C; Jakobsson, ME; Riedel, M; Norgaard, M; Hedensted, S; Dagnaes-Hansen, F; Ulhoi, BP; Eeles, R; Borre, M; Olsen, JV; Olsen, JV; Thomsen, M; Kote-Jarai, Z; Sorensen, KD (2020-11-28)
    Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly ...

View more